Stonepine Capital Management LLC Has $3.79 Million Stake in Indivior PLC (NASDAQ:INDV)

Stonepine Capital Management LLC lifted its position in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 13.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 305,000 shares of the company's stock after buying an additional 35,000 shares during the quarter. Indivior makes up about 3.1% of Stonepine Capital Management LLC's holdings, making the stock its 10th largest position. Stonepine Capital Management LLC owned about 0.22% of Indivior worth $3,791,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in INDV. Rathbones Group PLC grew its holdings in Indivior by 11.6% in the 4th quarter. Rathbones Group PLC now owns 14,284 shares of the company's stock valued at $183,000 after buying an additional 1,483 shares during the period. Stifel Financial Corp grew its holdings in shares of Indivior by 24.0% during the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company's stock worth $158,000 after purchasing an additional 2,450 shares during the period. PDT Partners LLC grew its holdings in shares of Indivior by 4.7% during the 4th quarter. PDT Partners LLC now owns 57,520 shares of the company's stock worth $715,000 after purchasing an additional 2,596 shares during the period. Clark Estates Inc. NY grew its holdings in shares of Indivior by 1.3% during the 4th quarter. Clark Estates Inc. NY now owns 257,400 shares of the company's stock worth $3,199,000 after purchasing an additional 3,300 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Indivior during the 4th quarter worth about $56,000. Institutional investors and hedge funds own 60.33% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on INDV. RODMAN&RENSHAW raised Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Piper Sandler cut their target price on Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th. Finally, Rodman & Renshaw started coverage on Indivior in a research report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 target price on the stock.

Indivior Price Performance

Shares of INDV stock traded down $0.15 on Wednesday, hitting $11.29. 509,100 shares of the stock traded hands, compared to its average volume of 1,012,604. The company has a market capitalization of $1.56 billion, a PE ratio of -32.26 and a beta of 0.98. Indivior PLC has a 1-year low of $7.33 and a 1-year high of $18.59. The company's fifty day moving average is $10.18 and its 200 day moving average is $10.66.

Indivior (NASDAQ:INDV - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.19. The business had revenue of $266.00 million for the quarter, compared to analyst estimates of $240.13 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. As a group, equities research analysts expect that Indivior PLC will post 1.22 EPS for the current year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.